Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST | Journal of Clinical Oncology
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
soria ar Twitter: "#ENA2016 Dr seymour @theNCI @EORTC @aacr on iRECIST goals and limitations https://t.co/2TBUcpcndq" / Twitter
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
iRECIST: how to do it | Cancer Imaging | Full Text
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
i RECIST A guideline for data management and
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Assessing Immunotherapy Response and Progression
i RECIST A guideline for data management and
iRECIST: how to do it | Cancer Imaging | Full Text
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
iRECIST Overview
iRECIST
EPOS™
Evaluation of CT scans of CIT patients: RECIST vs irRECIST/iRECIST, Mizuki Nishino - YouTube
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
iRECIST Overview
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
